记者21日从2025年上半年浙江经济运行情况新闻发布会获悉，根据地区生产总值统一核算结果，上半年 浙江全省地区生产总值45004亿元，按不变价格计算，同比增长5.8%。 "向智"即向智能化转型。褚英国介绍，今年上半年，浙江人工智能核心产业企业营业收入增速明显快于 规模以上企业。智能产品产销两旺，智能家用电器和音像器材、可穿戴智能设备、智能手机等商品零售 增速远高于浙江全省社会消费品零售总额的平均增速。 "上半年，浙江有力、有序、有效应对外部风险挑战，经济运行稳中有进、向新向好，有力扛起'经济大 省挑大梁'的责任担当。"褚英国说，下阶段，浙江要坚定信心、保持定力，在转变发展方式、优化产业 结构上下更大功夫，持续增强经济内生增长动能，全力推动经济持续回升向好，为全国大局多作贡献。 "向高"即向高端化迈进。今年上半年，浙江规模以上工业中，高技术制造业、数字经济核心产业制造 业、装备制造业和战略性新兴产业增加值同比分别增长12.7%、12.0%、11.1%和9.8%，分别拉动规模以 上工业增加值增长2.2%、2.1%、5.5%和3.5%。 "向新"即向新型化发展。今年1至5月，浙江规模以上企业(包括工业和服务业)的研 ...

Group 1 - The core viewpoint of the news highlights the recent performance of Green Leaf Pharmaceutical, which saw a significant stock price increase despite a decline in financial metrics [1][2] - Green Leaf Pharmaceutical's stock price rose by 9.46% to HKD 3.82 per share, with a trading volume of 307 million shares and a turnover of HKD 1.148 billion, indicating high market activity [1] - Over the past month, Green Leaf Pharmaceutical has experienced a cumulative increase of 78.97%, and a year-to-date increase of 60.83%, outperforming the Hang Seng Index by 21.47% [1] Group 2 - Financial data for Green Leaf Pharmaceutical shows total revenue of CNY 6.061 billion for the year ending December 31, 2024, a decrease of 1.33% year-on-year, and a net profit of CNY 472 million, down 11.4% year-on-year [1] - The company's gross profit margin stands at 66.72%, with a debt-to-asset ratio of 46.8% [1] - Currently, there are no institutional investment ratings for Green Leaf Pharmaceutical, and its price-to-earnings ratio is 25.76, ranking 53rd in the pharmaceutical and biotechnology industry, which has an average P/E ratio of 4.2 [2] Group 3 - Green Leaf Pharmaceutical focuses on the development, production, promotion, and sales of innovative drugs in major therapeutic areas such as oncology, central nervous system, cardiovascular, and digestive and metabolic diseases [3] - The company has a product portfolio of over 30 products, covering more than 80 countries and regions, including major pharmaceutical markets like China, the US, Europe, and Japan [3] - Green Leaf Pharmaceutical has established a nationwide sales and distribution network in China, reaching over 19,330 hospitals, including approximately 87% of tertiary hospitals and 66% of secondary hospitals [3] - The company has a strong research and development team consisting of 824 employees, including 73 PhDs and 438 master's degree holders, and holds numerous patents in both China and overseas [3]